|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Pathophysiology/Complications |
Insulin Sensitivity and Lipid Metabolism in Human CD36 Deficiency
From the Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
OBJECTIVE—CD36 has been proposed as a fatty acid translocase and a receptor for HDL and oxidized LDL. The association between CD36 deficiency and insulin resistance remains controversial. We investigated glucose and lipid metabolism in human CD36 deficiency.
RESEARCH DESIGN AND METHODS—A total of 61 type I CD36-deficient patients and 25 control subjects were examined. Diabetes was defined as fasting glucose level 
7 mmol/l or use of hypoglycemic agents. A homeostasis model assessment (HOMA) index was evaluated in patients without diabetes. Insulin resistance was defined as a HOMA index 1.73 (sensitivity 64.3%, specificity 78.9%; J Japan Diab Soc, 2000).
RESULTS—Diabetes was identified in 12 (20%) of the 61 CD36-deficient patients. Fasting glucose, HbA1c, and total cholesterol levels in the diabetic CD36-deficient patients were significantly higher than in the control subjects and the nondiabetic CD36-deficient patients. Regardless of diabetes, HDL cholesterol concentrations in the CD36-deficient patients were significantly higher than in the control subjects. The nondiabetic CD36-deficient patients had higher triglyceride concentrations than the control subjects, and triglyceride concentrations were higher in the diabetic CD36-deficient patients than in the nondiabetic CD36-deficient patients. The prevalence of insulin resistance in the nondiabetic CD36-deficient patients was similar to that in the control subjects.
CONCLUSIONS—Human CD36 deficiency is not necessarily responsible for insulin resistance. Lipid abnormalities in CD36 deficiency may partly depend on the presence of diabetes, and increased levels of triglyceride and HDL cholesterol may be due to impaired binding of fatty acids and HDL to CD36 and subsequent clearance.
Abbreviations: HOMA, homeostasis model assessment • LCFA, long-chain fatty acid • [123I]BMIPP, 123I-labeled 15-(p-iodophenyl)-3-R,S-methyl-pentadecanoic acid
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Yanai, H. Chiba, and K. Matsuno Elevated Plasma Plasminogen Activator Inhibitor-1 in CD36 Deficiency Diabetes Care, October 1, 2008; 31(10): e72 - e72. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Love-Gregory, R. Sherva, L. Sun, J. Wasson, T. Schappe, A. Doria, D.C. Rao, S. C. Hunt, S. Klein, R. J. Neuman, et al. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol Hum. Mol. Genet., June 1, 2008; 17(11): 1695 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Nassir, B. Wilson, X. Han, R. W. Gross, and N. A. Abumrad CD36 Is Important for Fatty Acid and Cholesterol Uptake by the Proximal but Not Distal Intestine J. Biol. Chem., July 6, 2007; 282(27): 19493 - 19501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Clee and A. D. Attie The Genetic Landscape of Type 2 Diabetes in Mice Endocr. Rev., February 1, 2007; 28(1): 48 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Bastie, Z. Nahle, T. McLoughlin, K. Esser, W. Zhang, T. Unterman, and N. A. Abumrad FoxO1 Stimulates Fatty Acid Uptake and Oxidation in Muscle Cells through CD36-dependent and -independent Mechanisms J. Biol. Chem., April 8, 2005; 280(14): 14222 - 14229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ma, S. Bacci, W. Mlynarski, L. Gottardo, T. Soccio, C. Menzaghi, E. Iori, R. A. Lager, A. R. Shroff, E. V. Gervino, et al. A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians Hum. Mol. Genet., October 1, 2004; 13(19): 2197 - 2205. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |